Literature DB >> 28130690

The role of patient's systemic characteristics and plateletcrit in developing toxic anterior segment syndrome after uneventful phaco surgery: A case-control study.

Serpil Yazgan1, Ugur Celik2,3, Orhan Ayar1, Suat Hayri Ugurbas1, Burcu Celik4, Mehmet Orçun Akdemir1, Silay Canturk Ugurbas1, Atilla Alpay1.   

Abstract

PURPOSE: To compare the systemic and ocular characteristics and laboratory findings of patients developing toxic anterior segment syndrome (TASS) after uneventful phaco surgery with unaffected subjects undergoing the same surgery in the same session.
DESIGN: A retrospective case-control study.
METHODS: The study group consisted of 26 eyes of 26 patients who underwent uneventful phaco surgery and who went on to develop TASS, while the control group included 39 subjects who had routine phaco surgery in the same session by the same surgeon. The sterilization stages of reusable instruments, disposable instruments, and compositions were recorded. The preoperative systemic diseases, complete blood count parameters, glycosylated hemoglobin (HbA1c), biochemical parameters, thyroid hormone profiles, and the surgical features were compared between the two groups.
RESULTS: Type 2 diabetes mellitus (DM), systemic hypertension (HT), hyperlipidemia, chronic ischaemic heart disease, and chronic renal failure were significantly more common in the TASS group (p < 0.05). Proliferative diabetic retinopathy was also more frequent in the TASS group (p = 0.003). Mean HbA1c% values, white blood cell count, neutrophil/lymphocyte ratio, platelet counts, platelet distribution width, and plateletcrit parameters were significantly higher in the TASS group (p < 0.05). Multivariate logistic regression analysis revealed that a high plateletcrit level (p = 0.001, odds ratio [95% CI]; 22.27 [3.36-147.76]) and systemic HT (p = 0.044, odds ratio [95% CI]; 7.13 [1.05-48.12]) are independently associated with the development of TASS.
CONCLUSION: Although TASS may arise as a result of insufficient sterilization of instruments or intraocular solutions, patient factors may also contribute to its development. Systemic vascular disorders such as uncontrolled type 2 DM, systemic hypertension, and hyperlipidemia may increase the risk of TASS after uneventful phaco surgery. Abnormal parameters associated with systemic inflammation, such as higher plateletcrit level, may facilitate the development of TASS. These findings may be a predicting factor of TASS development for uneventful cataract surgeries.

Entities:  

Keywords:  Plateletcrit; Systemic diseases; Toxic anterior segment syndrome

Mesh:

Year:  2017        PMID: 28130690     DOI: 10.1007/s10792-016-0418-x

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  43 in total

1.  Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon.

Authors:  Ibrahim Akpinar; Muhammet Rasit Sayin; Yusuf Cemil Gursoy; Ziyaeddin Aktop; Turgut Karabag; Emrah Kucuk; Nihat Sen; Mustafa Aydin; Sibel Kiran; Mustafa Cagatay Buyukuysal; Ibrahim Celal Haznedaroglu
Journal:  J Cardiol       Date:  2013-09-04       Impact factor: 3.159

2.  Outbreak of toxic anterior segment syndrome associated with glutaraldehyde after cataract surgery.

Authors:  Mustafa Unal; Iclal Yücel; Yusuf Akar; Asli Oner; Meryem Altin
Journal:  J Cataract Refract Surg       Date:  2006-10       Impact factor: 3.351

3.  An epidemic of corneal destruction caused by plasma gas sterilization. The Toxic Cell Destruction Syndrome Investigative Team.

Authors:  R E Duffy; S E Brown; K L Caldwell; A Lubniewski; N Anderson; H Edelhauser; G Holley; A Tess; H Divan; M Helmy; M Arduino; W R Jarvis
Journal:  Arch Ophthalmol       Date:  2000-09

4.  Toxic anterior segment syndrome following iris-supported phakic IOL implantation with viscoelastic Multivisc BD.

Authors:  Israel Kremer; Eliya Levinger; Samuel Levinger
Journal:  Eur J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 2.597

5.  Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia.

Authors:  Mehdi Mirsaeidi; Paula Peyrani; Stefano Aliberti; Giovanni Filardo; Jose Bordon; Francesco Blasi; Julio A Ramirez
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

6.  Inhibitory effects of tetrandrine on bovine serum albumin-induced uveitis in rabbits.

Authors:  J Xiao; S Wu; Y Wang; J Li; S Zhang
Journal:  J Ocul Pharmacol       Date:  1993

7.  Sterile endophthalmitis after sutureless cataract surgery.

Authors:  D B Nelson; E D Donnenfeld; H D Perry
Journal:  Ophthalmology       Date:  1992-11       Impact factor: 12.079

8.  The Food and Drug Administration's Proactive toxic anterior segment syndrome Program.

Authors:  Malvina B Eydelman; Michelle E Tarver; Don Calogero; Shelley Y Buchen; Kesia Y Alexander
Journal:  Ophthalmology       Date:  2012-05-11       Impact factor: 12.079

9.  Diabetic retinopathy and inflammation: novel therapeutic targets.

Authors:  Sampathkumar Rangasamy; Paul G McGuire; Arup Das
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01

10.  Development of toxic anterior segment syndrome immediately after uneventful phaco surgery.

Authors:  Jin Seok Choi; Kyung Hwan Shyn
Journal:  Korean J Ophthalmol       Date:  2008-12
View more
  3 in total

1.  Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study.

Authors:  Prashanth G Iyer; Marc C Peden; Ivan J Suñer; Nish Patel; Sander R Dubovy; Thomas A Albini
Journal:  Am J Ophthalmol Case Rep       Date:  2020-11-10

2.  Two Cases of Consecutive Toxic Anterior Segment Syndrome after Uneventful Trabeculectomy Surgeries in a Tertiary Center.

Authors:  Tatiana M Gil-Martínez; María J Herrera; Vanessa Vera
Journal:  Case Rep Ophthalmol       Date:  2022-04-04

Review 3.  Toxic anterior segment syndrome-an updated review.

Authors:  Choul Yong Park; Jimmy K Lee; Roy S Chuck
Journal:  BMC Ophthalmol       Date:  2018-10-25       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.